Chavassieux P, Chapurlat R, Portero-Muzy N, et al. - In postmenopausal women with osteoporosis, researchers described the impact of romosozumab, a humanized sclerostin antibody, on bone tissue by bone histomorphometry early in treatment at 2 months, and assessed in another patient cohort the evolution of these effects after 12 months of romosozumab administration. Transiliac bone biopsies were performed for 107 patients at either month 2 (n = 34) or month 12 (n = 73) with a 7.5-mm inner diameter trephine. Investigators found that romosozumab resulted in an early and transient increase in bone formation, but a persistent reduction in bone resorption. Eventually, antiresorptive action led to lower bone turnover. This effect led to significant bone mass increases and improved microarchitecture. No significant change in periosteal and endocortical bone was observed.